• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study.氨磺必利对精神分裂症患者精神病理学五个维度的影响：一项前瞻性开放标签研究。
BMC Psychiatry. 2005 May 3;5:22. doi: 10.1186/1471-244X-5-22.
2
Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation?氨磺必利在急性加重期精神分裂症患者康复中起何种作用？
Encephale. 2000 Oct;26 Spec No 1:7-11.
3
Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study.氨磺必利改善服用非典型抗精神病药物的精神分裂症患者的强迫症状：一项开放标签转换研究。
J Clin Psychopharmacol. 2008 Jun;28(3):349-52. doi: 10.1097/JCP.0b013e318172755a.
4
Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group.使用氨磺必利治疗原发性阴性症状的精神分裂症患者的改善情况。氨磺必利研究组。
Am J Psychiatry. 1999 Apr;156(4):610-6. doi: 10.1176/ajp.156.4.610.
5
Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature.氯氮平与氨磺必利联合治疗难治性精神分裂症——病例报告及文献综述
Pharmacopsychiatry. 2004 Jan;37(1):26-31. doi: 10.1055/s-2004-815471.
6
[Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses].氨磺必利治疗精神分裂症性精神病的疗效及耐受性评估
Encephale. 1998 Jul-Aug;24(4):386-92.
7
[Effectiveness and tolerability of amisulpride in patients with schizophrenia: results of a 6-month open study].氨磺必利治疗精神分裂症患者的有效性和耐受性：一项6个月开放性研究的结果
Psychiatr Pol. 2004 May-Jun;38(3):453-68.
8
Combined use of amisulpride and clozapine for patients with treatment-resistant schizophrenia.氨磺必利与氯氮平联合用于难治性精神分裂症患者。
Australas Psychiatry. 2004 Mar;12(1):74-6. doi: 10.1046/j.1039-8562.2003.02064.x.
9
Amisulpride for the treatment of very-late-onset schizophrenia-like psychosis.氨磺必利治疗极晚发性类似精神分裂症的精神病。
Int J Geriatr Psychiatry. 2009 May;24(5):518-22. doi: 10.1002/gps.2146.
10
How do we choose between atypical antipsychotics? The advantages of amisulpride.我们如何在非典型抗精神病药物中进行选择？氨磺必利的优势。
Int J Neuropsychopharmacol. 2004 Mar;7 Suppl 1:S21-5. doi: 10.1017/S1461145704004134.

引用本文的文献

1
Association between Insertion-Deletion Polymorphism of the Angiotensin-Converting Enzyme Gene and Treatment Response to Antipsychotic Medications: A Study of Antipsychotic-Naïve First-Episode Psychosis Patients and Nonadherent Chronic Psychosis Patients.血管紧张素转化酶基因插入/缺失多态性与抗精神病药物治疗反应的关系：一项针对抗精神病药物初发精神分裂症患者和非依从性慢性精神分裂症患者的研究。
Int J Mol Sci. 2022 Oct 12;23(20):12180. doi: 10.3390/ijms232012180.
2
Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study.氨磺必利与奥氮平治疗阴性症状和认知障碍的疗效：一项开放标签临床研究。
Ind Psychiatry J. 2014 Jan;23(1):27-35. doi: 10.4103/0972-6748.144953.
3
Almost all antipsychotics result in weight gain: a meta-analysis.几乎所有抗精神病药物都会导致体重增加：一项荟萃分析。
PLoS One. 2014 Apr 24;9(4):e94112. doi: 10.1371/journal.pone.0094112. eCollection 2014.
4
Update on the management of symptoms in schizophrenia: focus on amisulpride.精神分裂症症状管理的最新进展：重点关注氨磺必利。
Neuropsychiatr Dis Treat. 2009;5:267-77. doi: 10.2147/ndt.s3949. Epub 2009 May 20.
5
Differential diagnoses and management strategies in patients with schizophrenia and bipolar disorder.精神分裂症和双相情感障碍患者的鉴别诊断和治疗策略。
Neuropsychiatr Dis Treat. 2008 Feb;4(1):311-7. doi: 10.2147/ndt.s2703.
6
Adverse effects of atypical antipsychotics in the elderly: a review.老年患者使用非典型抗精神病药物的不良反应：综述
Drugs Aging. 2006;23(12):937-56. doi: 10.2165/00002512-200623120-00002.

本文引用的文献

1
Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride.精神分裂症患者的认知改善并不需要血清素能机制：奥氮平与氨磺必利的随机对照试验
Neuropsychopharmacology. 2005 Feb;30(2):381-90. doi: 10.1038/sj.npp.1300626.
2
A forced five-dimensional factor analysis and concurrent validity of the Positive and Negative Syndrome Scale in Mexican schizophrenic patients.墨西哥精神分裂症患者中阳性与阴性症状量表的强迫性五因素分析及同时效度
Schizophr Res. 2005 Jan 1;72(2-3):123-9. doi: 10.1016/j.schres.2004.03.021.
3
A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia.阿立哌唑与奥氮平治疗精神分裂症6个月的双盲随机对照试验。
Int Clin Psychopharmacol. 2004 Mar;19(2):63-9. doi: 10.1097/00004850-200403000-00002.
4
What's atypical about atypical antipsychotic drugs?非典型抗精神病药物的非典型之处体现在哪里？
Curr Opin Pharmacol. 2004 Feb;4(1):53-7. doi: 10.1016/j.coph.2003.09.010.
5
How do we choose between atypical antipsychotics? The advantages of amisulpride.我们如何在非典型抗精神病药物中进行选择？氨磺必利的优势。
Int J Neuropsychopharmacol. 2004 Mar;7 Suppl 1:S21-5. doi: 10.1017/S1461145704004134.
6
Amisulpride is an "atypical" antipsychotic associated with low weight gain.氨磺必利是一种与体重增加较少相关的“非典型”抗精神病药物。
Psychopharmacology (Berl). 2004 Apr;173(1-2):112-5. doi: 10.1007/s00213-003-1721-6. Epub 2003 Nov 28.
7
Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan.氨磺必利与利培酮治疗精神分裂症患者的对照研究：台湾地区一项双盲试验性研究
J Formos Med Assoc. 2003 Jan;102(1):30-6.
8
A confirmatory factor analytic evaluation of the pentagonal PANSS model.五边形阳性与阴性症状量表（PANSS）模型的验证性因素分析评估
Schizophr Res. 2003 May 1;61(1):97-104. doi: 10.1016/s0920-9964(02)00295-5.
9
Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study.氨磺必利与利培酮治疗慢性精神分裂症的6个月双盲研究结果
Neuropsychopharmacology. 2002 Dec;27(6):1071-81. doi: 10.1016/S0893-133X(02)00375-5.
10
Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia.氨磺必利对精神分裂症急性加重期患者精神病理学五个维度的剂量相关效应。
J Clin Psychopharmacol. 2002 Dec;22(6):554-60. doi: 10.1097/00004714-200212000-00004.

氨磺必利对精神分裂症患者精神病理学五个维度的影响：一项前瞻性开放标签研究。

The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study.

作者信息

Herrera-Estrella Miguel, Apiquian Rogelio, Fresan Ana, Sanchez-Torres Isabel

机构信息

Psychiatry Department, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.

出版信息

BMC Psychiatry. 2005 May 3;5:22. doi: 10.1186/1471-244X-5-22.

DOI:10.1186/1471-244X-5-22
PMID:15869707
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1090597/
Abstract

BACKGROUND

The efficacy of antipsychotics can be evaluated using the dimensional models of schizophrenic symptoms. The D2/D3-selective antagonist amisulpride has shown similar efficacy and tolerability to other atypical antipsychotics. The aim of the present study was to determine the efficacy of amisulpride on the dimensional model of schizophrenic symptoms and tolerability in latin schizophrenic patients.

METHOD

Eighty schizophrenic patients were enrolled and 70 completed a prospective open-label 3-month study with amisulpride. The schizophrenic symptoms, psychosocial functioning and side-effects were evaluated with standardized scales.

RESULTS

The patients showed significant improvement in the five dimensions evaluated. Amisulpride (median final dose 357.1 mg/d) was well-tolerated without treatment-emergent extrapyramidal side-effects.

CONCLUSION

Amisulpride showed efficacy on different psychopathological dimensions and was well tolerated, leading to consider this drug a first line choice for the treatment of schizophrenia.

摘要

背景

抗精神病药物的疗效可通过精神分裂症症状的维度模型进行评估。D2/D3选择性拮抗剂阿立哌唑已显示出与其他非典型抗精神病药物相似的疗效和耐受性。本研究的目的是确定阿立哌唑对拉丁裔精神分裂症患者精神分裂症症状维度模型的疗效和耐受性。

方法

招募了80名精神分裂症患者，其中70名完成了一项为期3个月的阿立哌唑前瞻性开放标签研究。使用标准化量表评估精神分裂症症状、心理社会功能和副作用。

结果

患者在评估的五个维度上均有显著改善。阿立哌唑（最终中位剂量357.1毫克/天）耐受性良好，未出现治疗中出现的锥体外系副作用。

结论

阿立哌唑在不同的精神病理维度上显示出疗效，且耐受性良好，因此可将该药物视为治疗精神分裂症的一线选择。